Targeting cancer by a chimeric nanoparticle formulation of Cisplatin and PI828, a PI3 kinase inhibitor

被引：0
|
作者：
Roy, Bhaskar [1 ]
Sengupta, Poulomi [1 ]
Dinulescu, Daniela [1 ]
Muto, Katherine [1 ]
Papa, Anne Laure [1 ]
Basu, Sudipta [1 ]
Sengupta, Shiladitya [1 ]
机构：
[1] Brigham & Womens Hosp, Cambridge, MA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1951
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1951
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Identification of PKI-179 as a potent and orally efficacious PI3 kinase inhibitor for the treatment of cancer
    Chen, Zecheng
    Venkatesan, Aranapakam M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [32] The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
    Carden, Craig P.
    Stewart, Adam
    Thavasu, Parames
    Kipps, Emma
    Pope, Lorna
    Crespo, Mateus
    Miranda, Susana
    Attard, Gerhardt
    Garrett, Michelle D.
    Clarke, Paul A.
    Workman, Paul
    de Bono, Johann S.
    Gore, Martin
    Kaye, Stan B.
    Banerji, Udai
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (07) : 1609 - 1617
  • [33] A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway.
    Rafil, Saeed
    Roda, Desamparados
    Geuna, Elena
    Rodriguez, Begone Jimenez
    Rlhawl, Karim
    Capelan, Marta
    Yap, Timothy Anthony
    Kaye, Stanley B.
    Mollfe, L. Rhoda
    De Bono, Johann Sebastian
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Targeting CDK4/6 inhibitor resistance in relapsed osteosarcoma via PI3 Kinase inhibition.
    Barghi, Farinaz
    Pandya, Pankita H.
    Saadatzadeh, M. Reza
    Bijangi-Vishehsaraei, Khadijeh
    Bailey, Barbara J.
    Dobrota, Erika A.
    Young, Courtney
    Trowbridge, Melissa A.
    Coy, Kathy
    Sinn, Anthony L.
    Shannon, Harlan E.
    Renbarger, Jamie L.
    Pollok, Karen E.
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Targeting Epigenetic Resistance Mechanisms to PI3 Kinase Inhibition in Leukemic Stem Cells
    Glushakow-Smith, Shira
    Kaur, Imit
    Sidoli, Simone
    Hemmati, Shayda
    Angeles, Ellen
    Sinclair, Taneisha
    Battle, Aaliyah
    Verma, Amit
    Gritsman, Kira
    BLOOD, 2023, 142
  • [36] PI3 kinase targeting agents: XL147 and XL765
    DeCillis, A.
    Baselga, J.
    Edelman, G.
    LoRusso, P.
    Markman, B.
    Papadopoulous, K.
    Shapiro, G.
    Aggarwal, S.
    Nguyen, L.
    Laird, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [37] Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor
    Peng, Xiaodong
    Su, Jing Dong
    Garlich, Joseph R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3594S - 3595S
  • [38] Synergistic Growth Inhibition with a PI3 Kinase/mTOR Inhibitor Plus Lapatinib.
    Speicher, T. J.
    Hackl, W.
    Lipton, A.
    CANCER RESEARCH, 2009, 69 (24) : 861S - 861S
  • [39] Assessment of PI3 kinase as a druggable target in melanoma
    Aziz, S. A.
    Pick-Golan, E.
    McCarthy, M. M.
    Flaherty, K. T.
    Camp, R. L.
    Rimm, D. L.
    Kluger, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Regulation of cardiac substrate metabolism by PI3 kinase
    Mazumder, PK
    Graveleau, C
    Tuttle, MJ
    Betuing, S
    Belke, DD
    Shioi, T
    Izumo, S
    Abel, ED
    CIRCULATION, 2002, 106 (19) : 157 - 157
12345